Persisting cancer cells are different from bacterial persisters.

Decollogny, Morgane; Rottenberg, Sven (2024). Persisting cancer cells are different from bacterial persisters. (In Press). Trends in cancer Elsevier 10.1016/j.trecan.2024.02.002

[img]
Preview
Text
1-s2.0-S2405803324000281-main.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (949kB) | Preview

The persistence of drug-sensitive tumors poses a significant challenge in cancer treatment. The concept of bacterial persisters, which are a subpopulation of bacteria that survive lethal antibiotic doses, is frequently used to compare to residual disease in cancer. Here, we explore drug tolerance of cancer cells and bacteria. We highlight the fact that bacteria, in contrast to cancer cells, have been selected for survival at the population level and may therefore possess contingency mechanisms that cancer cells lack. The precise mechanisms of drug-tolerant cancer cells and bacterial persisters are still being investigated. Undoubtedly, by understanding common features as well as differences, we, in the cancer field, can learn from microbiology to find strategies to eradicate persisting cancer cells.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Animal Pathology
04 Faculty of Medicine > Faculty Institutions > Bern Center for Precision Medicine (BCPM)

UniBE Contributor:

Decollogny, Morgane Francine, Rottenberg, Sven

Subjects:

600 Technology > 610 Medicine & health
600 Technology > 630 Agriculture

ISSN:

2405-8025

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

04 Mar 2024 14:51

Last Modified:

04 Mar 2024 14:57

Publisher DOI:

10.1016/j.trecan.2024.02.002

PubMed ID:

38429144

Uncontrolled Keywords:

bacterial persisters drug resistance drug tolerance epigenetics quiescence residual disease in cancer

BORIS DOI:

10.48350/193724

URI:

https://boris.unibe.ch/id/eprint/193724

Actions (login required)

Edit item Edit item
Provide Feedback